ArunSayramSinghMD

Hematologic Oncology, Sarcoma

Assistant Professor, UCLA School of Medicine

Dr. Singh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2825 Santa Monica Blvd
Ste 200
Santa Monica, CA 90404
Phone+1 310-829-5471

Fax+1 310-453-8309

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2008
Rutgers New Jersey Medical SchoolClass of 2005

PubMed

39 citations
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes
Elizabeth Shurell, Arun S. Singh, Joseph G. Crompton, Sarah Jensen, Yunfeng Li
Oncotarget. 2016-08-31
63 citations
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.
Theodore S. Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, Rong Rong Huang, Xiaoyan Wang
Clinical Cancer Research. 2019-04-01
366 citations
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang
The New England Journal of Medicine. 2015-07-29

Journal Articles

Lectures

A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor(GIST).
2019 ASCO Annual Meeting - 6/1/2019

OncLive® Presents State of the Science Summit™: Treatment of Ovarian CancerMay 21st, 2018
Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory BoardSeptember 29th, 2016